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a b s t r a c t
The effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, alone and in combination with
voglibose or exendin-4, on glycaemic control and body weight were assessed in an animal model of type
2 diabetes. Voglibose is an α-glucosidase inhibitor but also increases glucagon-like peptide 1 (GLP-1).
Exendin-4 is a GLP-1 receptor agonist. Male Zucker Diabetic Fatty (ZDF) rats were dosed for 3 days, fasted
overnight and a sucrose/glucose tolerance test was performed. Linagliptin (1 mg/kg po) improved
glucose tolerance by increasing plasma GLP-1 (active) and insulin secretion, whilst having no effect on
body weight. Voglibose (1 and 10 mg/kg po) reduced body weight, improved glycaemic control, reduced
plasma insulin and increased total but not active GLP-1. The combination of linagliptin and voglibose
signiﬁcantly reduced body weight, improved glycaemic control and reduced plasma insulin compared to
linagliptin alone. Furthermore, linagliptin plus voglibose produced a marked increase in GLP-1 (active) at
5 min post-sucrose, compared to linagliptin, possibly because linagliptin prevented the degradation of
GLP-1 secreted in response to voglibose. Exendin-4 (10 μg/kg sc) signiﬁcantly reduced body weight,
improved glucose tolerance but reduced GLP-1 (active). The combination of linagliptin and exendin-4
signiﬁcantly reduced body weight and improved glycaemic control but had no effect on plasma GLP-1.
Overall it did not markedly improve glycaemic control compared to the individual drugs. The improved
glucose control, reduced body weight and markedly increased plasma GLP-1 levels in animals given
linagliptin with voglibose, suggests that this combination may be particularly beneﬁcial in the treatment
of type 2 diabetes.
& 2014 The Authors. Published by Elsevier B.V.
1. Introduction
Type 2 diabetes is a chronic, progressive disease characterised
by hyperglycaemia, which arises from the development of insulin
resistance in peripheral tissues, a failure of the pancreatic β-cells
to secrete sufﬁcient insulin in response to glucose loads, and an
inadequate suppression of glucagon production (Spellman, 2010).
The prevalence of diabetes continues to increase and globally the
World Health Organisation (WHO) estimates that 347 million
people suffer from diabetes, with approximately 90% having
type 2 diabetes (WHO, 2012). Type 2 diabetes is associated with
increased morbidity and mortality due to macrovascular and
microvascular complications leading to an increased risk of heart
disease, stroke, neuropathy, retinopathy and kidney disease (WHO,
2012; Papa et al., 2013).
Glucagon-like peptide 1 (GLP-1) is an incretin hormone, which is
released from the intestine following a meal. It exerts a glucose-
dependent insulinotropic action in β-cells, inhibits the secretion of
glucagon and restores β-cell mass (Drucker, 2006). GLP-1 has an
antidiabetic action in type 2 diabetic patients and is a popular
pharmacological target for the development of new drugs to treat
this disorder (Meier and Nauck, 2006; Todd and Bloom, 2007).
GLP-1 has a very short half-life in plasma and one therapeutic
approach has been to prevent the degradation of biologically active
forms of GLP-1 [GLP-1-(7-36) amide and GLP-1-(7-37)] by dipepti-
dyl peptidase-4 (DPP-4, EC 3.4.14.5) (Pratley and Salsali, 2007).
Linagliptin is a highly selective DPP-4 inhibitor which has
recently been approved for the treatment of type 2 diabetes in
the USA and European Union (Aletti and Cheng-Lai, 2012; Brown
and Evans, 2012; Gallwitz, 2013; Rauch et al., 2012). Preclinical
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studies have shown that linagliptin inhibits DPP-4 more potently
and with a longer duration of action than other DPP-4 inhibitors
such as sitagliptin, vildagliptin, saxagliptin and alogliptin (Thomas
et al., 2008, 2009). A further advantage of linagliptin, compared to
other members of this drug class, is that it is eliminated by the
biliary/hepatic route, rather than by the kidneys, and can be used
without dose modiﬁcation in patients with renal insufﬁciency, a
common complaint in type 2 diabetes (Barnett, 2011; Graefe-
Mody et al., 2012).
Polytherapy is an accepted strategy for improving the treat-
ment of diabetes (Wright et al., 2010). The main aim of the present
study was to investigate whether combinations of linagliptin with
voglibose or exendin-4, improved glycaemic control compared to
the different treatments given alone. Voglibose and exendin-4 are
currently used for the treatment of diabetes. Voglibose is an
α-glucosidase inhibitor (Chen et al., 2006) but also increases
GLP-1 secretion (Moritoh et al., 2009, 2010) whereas exendin-4
is a GLP-1 receptor agonist (Bray, 2006).
Studies were conducted in male Zucker Diabetic Fatty (ZDF)
rats, an established genetically-predisposed model of diabetes
(Etgen and Oldham, 2000). Animals were given the different drugs
for 3 days, fasted overnight, and on Day 4, following baseline blood
sampling and drug administration, a sucrose or glucose tolerance
test was performed. Effects of the different treatments on plasma
glucose, insulin, active and total GLP-1, DPP-4 activity and body
weight were measured.
2. Materials and methods
2.1. Animals and environment
Male ZDF-leprfa/Crl rats (6 weeks of age) were obtained from
Charles River, USA and housed individually with free access to
normal rat chow (Harlan Teklad Global Diet 2018) and tap water.
Animals were maintained at 2174 1C and 55720% humidity on a
normal phase 12 h light dark cycle (lights on 07:00 h–19:00 h) and
were allowed to habituate to the facility for approximately one
week prior to the initiation of procedures.
2.2. Experimental procedures
Three separate studies were conducted in the same cohort of
animals with a washout period of at least 9 treatment-free days
between experiments. A few days prior to each study, animals
were weighed and fasting plasma glucose levels were determined.
These data were used to allocate the rats into balanced treatment
groups (n¼10). Animals were drug-naïve at the start of the ﬁrst
study. Previous drug history was taken into account when rats
were allocated into groups for the second and third study to
ensure that groups were balanced and to control for any residual
drug effects. For practical reasons, animals used for the ﬁrst two
studies were divided into two balanced cohorts with half of the
animals undergoing procedures a day in advance of the other half.
During each study, body weights were recorded on each day
before dosing (which commenced at 10:30 h).
In the ﬁrst study, animals were dosed orally with vehicle,
linagliptin (1 mg/kg), voglibose (10 mg/kg) or the combination of
linagliptin with voglibose once daily for 3 days. Drug doses were
based on previous in vivo experiments (linagliptin: Thomas et al.,
2008, 2009; voglibose: Moritoh et al., 2009, 2010). At approxi-
mately 16:00 h on Day 3, food (but not water) was withdrawn. The
following morning, the lateral tail vein of each rat was cannulated
and a baseline blood sample (B1) was collected into a lithium–
heparin tube. Animals were dosed with vehicle or drug as normal.
Thus, rats received 4 drug treatments in total. Approximately 1 h
later, a second baseline blood sample (B2) was taken. Animals
were immediately dosed with sucrose (4 g/kg po) and blood
samples were taken 5, 15, 30, 60 and 120 min later. Sucrose was
used as the challenge for voglibose due to its mode of action in the
gastrointestinal tract. Tail vein cannulae were then removed. Blood
samples were centrifuged and plasma stored frozen (80 1C) until
determination of plasma glucose (all time-points), insulin (B1 and
15 min time-points only), total GLP-1 (B1 time-point) and DPP-4
activity (B2 time-point). At the 5 min time-point, an additional
blood sample was collected into an EDTA-coated tube containing a
protease inhibitor cocktail (Sigma, P2714) and DPP-4 inhibitor
(Millipore DPP4-010), centrifuged and plasma stored frozen
(80 1C) for determination of plasma levels of active GLP-1. The
reason why insulin and active GLP-1 levels were only measured at
certain time-points was because of the restriction on the total
volume of blood that could be collected from each animal over the
time-course of the study. Thus, time-points for the insulin and
active GLP-1 determinations (which require relatively large
amounts of plasma compared to the glucose determinations) were
chosen to capture the highest excursions in insulin and GLP-1
following the sucrose or glucose challenge.
In the second study, animals were dosed orally with linagliptin
(1 mg/kg), either alone or in combination with subcutaneous
administration of exendin-4 (10 μg/kg). Doses of exendin-4 were
based on those used in previous in vivo studies (Mack et al., 2006;
Young et al., 1999). The experiment included control animals
which were dosed with the vehicle for linagliptin po and vehicle
for exendin-4 sc. Experimental procedures were the same as
described above, except that on Day 4, animals were challenged
with D-glucose 2 g/kg po instead of sucrose.
Following the results of the ﬁrst study, which suggested that
the combination of linagliptin and voglibose may be particularly
beneﬁcial in the treatment of diabetes (see Section 4), a third
study (similar in design to Study 1) was performed using linaglip-
tin and a lower dose of voglibose (1 mg/kg po). For clarity the two
studies with voglibose have been described together in Section 3.
2.3. Compounds
Linagliptin (Boehringer Ingelheim Pharma GmbH and Co. KG,
Biberach an der Riss, Germany) and voglibose (Tocris Bioscience,
Bristol, UK) were dissolved in 0.5% Natrosol solution. Exendin-4
(American Peptide Company, Sunnyvale, CA, USA) was dissolved in
sterile saline. Sucrose (Sigma, UK) and D-glucose (Fisher Scientiﬁc,
UK) were dissolved in deionised water. All compounds were dosed
as free base using a dose volume of 5 ml/kg for po administration
and 2 ml/kg for sc administration.
2.4. Plasma analyses
Plasma glucose levels were determined using a clinical glucose
assay reagent (Thermo Inﬁnity Glucose Reagent Cat No TR15421;
Thermo Electron Corp, PA, USA). Plasma insulin levels were
measured using an Ultrasensitive rat insulin enzyme-linked
immunosorbant assay (ELISA) kit (Mercodia, Uppsala, Sweden).
Plasma GLP-1 (active and total) levels were determined using
active and total GLP-1 ELISA kits (Millipore, MO, USA). DPP-4 acti-
vity in plasma was assessed as described by Thomas et al. (2008).
2.5. Statistical analysis
Body weights were analysed by two-way analysis of covariance
with treatment and cohort as factors and Day 1 body weight
(immediately before drug treatment commenced) as a covariate
(Studies 1 and 2) or one-way analysis of covariance with treatment
as a factor and Day 1 body weight as covariate (Study 3). Thus,
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body weight means were adjusted for differences between the
treatment groups at baseline (Day 1) and standard errors of the
mean (S.E.M.) were calculated from the residuals of the statistical
model. All mean body weight values on Day 1 were identical (and
S.E.M. were therefore zero) because the analysis of covariance
adjusted them all to equal the ‘grand mean’ of the values on this
day. Analysis of plasma glucose, insulin, GLP-1 (active and total)
and DPP-4 activity was by robust regression using M estimation,
Huber weighting, using the default parameter c¼1.345 or by a
general linear model (plasma insulin data, Study 3). Where
appropriate, data were log transformed and means were back-
transformed. The statistical models included treatment and cohort
or assay day (if applicable) as factors and bleeding order and Day
1 body weight as covariates. Baseline fasting plasma glucose levels
(used to allocate the rats into groups) were also used a covariate
for the plasma glucose data. Treatment groups were compared at
each time-point. The plasma glucose data has also been expressed
as the area under the curve above the B2 baseline (AUCB2) for
the 0–30 and 0–120 min time periods (AUCB20–30 min and
AUCB20–120 min, respectively).
Comparisons against the vehicle-treated control group and to
compare combination treatments to their individual constituents
for each individual study were by the multiple t test. Some
variation in GLP-1 and insulin responses in the linagliptin group
were observed between the studies therefore statistical analysis of
the GLP-1 and insulin data from all three experiments was
performed to determine if there was any evidence of a treatment
by study interaction for the linagliptin and vehicle treatment
groups (using a mixed linear model with treatment, study and
the treatment by study intervention as mixed factors and animals
as a random factor). However, no signiﬁcant differences were
observed, indicating that there was no residual effect of previous
drug treatment on subsequent experiments.
Po0.05 was the level accepted for statistical difference and
tests were carried out as two-sided tests. All statistical analyses
were performed by a qualiﬁed statistician using SASs software.
3. Results
3.1. Linagliptin and voglibose
Administration of linagliptin (1 mg/kg po) for 3 days did not
signiﬁcantly alter body weight in male ZDF rats, compared to the
control group (Fig. 1A). In comparison, voglibose (10 mg/kg po)
signiﬁcantly reduced body weight from Day 2 onwards, and body
weights of rats given linagliptin and voglibose (10 mg/kg po) were
signiﬁcantly lower than those of the controls, and the linagliptin
group, on Days 2, 3 and 4 (Fig. 1A).
Plasma glucose levels of the linagliptin-treated animals
were not signiﬁcantly different to the control group at B1 (the
baseline sample taken before drug treatment on the day of the oral
sucrose tolerance test). However, plasma glucose levels of rats
given linagliptin in combination with voglibose (10 mg/kg po) or
voglibose (10 mg/kg po) alone were signiﬁcantly reduced com-
pared to the controls at this time-point (Fig. 1B). None of the drugs
signiﬁcantly altered plasma glucose at B2 (60 min after treatment;
Fig. 1B). Linagliptin, voglibose (10 mg/kg po) and the combination
of linagliptin and voglibose (10 mg/kg po) signiﬁcantly reduced
plasma glucose following the sucrose load compared to the control
group as shown by the time course and AUCB2 data (Fig. 1B and
Table 1). The combination of linagliptin and voglibose (10 mg/kg
po) reduced plasma glucose at earlier time-points (5 and 15 min
post-sucrose) and to a signiﬁcantly greater extent (15, 30 and
120 min post-sucrose, AUCB20–30 min and AUCB20–120 min) than
linagliptin alone (Fig. 1B and Table 1).
Plasma insulin levels of rats given linagliptin or the combina-
tion of linagliptin and voglibose (10 mg/kg po) were not signiﬁ-
cantly different to the control group at B1, however, this parameter
was signiﬁcantly reduced by voglibose alone (Table 1). Linagliptin
signiﬁcantly increased, whereas voglibose (10 mg/kg po) and the
combination of linagliptin and voglibose (10 mg/kg po), signiﬁ-
cantly reduced plasma insulin levels, 15 min following the sucrose
challenge, compared to the vehicle-treated controls (Table 1).
Plasma insulin levels of animals given the combination were
signiﬁcantly lower than the linagliptin group and signiﬁcantly
higher than the voglibose (10 mg/kg po) group at 15 min post-
sucrose (Table 1).
Plasma DPP-4 activity at B2 was markedly inhibited in rats
given linagliptin or the combination of linagliptin and voglibose
(10 mg/kg po) compared to the controls (Table 1). Voglibose
(10 mg/kg po) produced a small, signiﬁcant reduction in this
parameter (Table 1). The combination of linagliptin and voglibose
(10 mg/kg po) inhibited plasma DPP-4 activity by signiﬁ-
cantly more than voglibose (10 mg/kg po) or linagliptin alone
(Table 1).
Treatment with linagliptin produced a small, signiﬁcant
reduction in plasma total GLP-1 levels at B1 compared to the
control group (Table 1). However, basal levels of total GLP-1 were
markedly and signiﬁcantly increased in animals given voglibose
Fig. 1. Effect of linagliptin (1 mg/kg po) and voglibose (10 mg/kg po), alone and in combination, on (A) body weight, and (B) plasma glucose levels during an oral sucrose
tolerance test, in male ZDF rats. Vehicle or drugs were administered once a day for 3 days. The oral sucrose tolerance test was performed on Day 4 following an overnight fast.
Plasma samples were taken before drug treatment (B1); 60 min after treatment (B2, 0 min) and 5, 15, 30, 60, and 120 min following a sucrose (4 g/kg po) challenge. Data are
shown as adjusted means (n¼10)7S.E.M. (Calculated from the residuals of the statistical model). nPo0.05, nnPo0.01, nnnPo0.001 versus vehicle-controls, ΨPo0.05,
ΨΨPo0.01, ΨΨΨPo0.001 combination versus linagliptin. The colours of the symbols match the corresponding graph. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)
R.B. Jones et al. / European Journal of Pharmacology 729 (2014) 59–66 61
(10 mg/kg po) or the combination of linagliptin and voglibose,
compared to the vehicle-treated group (Table 1). Total GLP-1
levels in animals given the combination were not signiﬁcantly
different to those of animals given voglibose but were signiﬁ-
cantly higher than those of the linagliptin group (Table 1). In
comparison, plasma levels of active GLP-1 (determined approxi-
mately 1 h following drug treatment and 5 min post-sucrose)
were signiﬁcantly increased by linagliptin and the combination of
linagliptin and voglibose (10 mg/kg po) but not by voglibose
(10 mg/kg po) alone, compared to the control group (Table 1). The
increase in active GLP-1 produced by the combination of drugs
was markedly (and signiﬁcantly) higher than the increase in
plasma levels of active GLP-1 produced by linagliptin alone
(Table 1).
The study was repeated using a lower dose of voglibose (Fig. 2
and Table 2). Linagliptin had no effect on body weight, voglibose
(1 mg/kg po) signiﬁcantly reduced body weight from Day 3, and
the combination of linagliptin and voglibose (1 mg/kg po) sig-
niﬁcantly reduced body weight from Day 2, compared to the
control group (Fig. 2A). Body weights of animals given linagliptin
and voglibose (1 mg/kg po) were signiﬁcantly lower than those of
rats given linagliptin or voglibose alone on Days 2 and 3, and
linagliptin alone, on Day 4 (Fig. 2A).
Linagliptin and voglibose (1 mg/kg po) had no effect on plasma
glucose at B1 or B2 when given alone, but the combination of the
two drugs signiﬁcantly reduced plasma glucose at these time-points,
to below control levels (Fig. 2B). Plasma glucose levels of animals
given linagliptin and voglibose (1 mg/kg po) were signiﬁcantly lower
than those of the voglibose group at B1 and B2 (Fig. 2B). All drug
treatments signiﬁcantly reduced plasma glucose levels following the
sucrose challenge, compared to the vehicle-treated controls (Fig. 2B
and Table 2). This response was signiﬁcantly greater in animals given
the combination, compared to linagliptin alone, at 15 min post-
sucrose, and compared to voglibose (1 mg/kg po) alone, at all time-
points after the sucrose load (Fig. 2B). Thus, the combination of
linagliptin and voglibose (1 mg/kg po) produced greater glucose
control than either drug given alone at 15 min post-sucrose
(Fig. 2B). These initial differences in plasma glucose control were
not signiﬁcant when the data were expressed as plasma glucose
AUCB20–30 min or AUCB20–120 min (Table 2).
Table 1
Effect of linagliptin (1 mg/kg po) and voglibose (10 mg/kg po), alone and in combination, on various plasma parameters during an oral
sucrose tolerance test in male ZDF rats.
Plasma parameter Vehicle po Linagliptin
1 mg/kg po
Voglibose
10 mg/kg po
Linagliptin 1 mg/kg poþ
voglibose 10 mg/kg po
Glucose AUCB2 (0–30 min, mM.h) 3.1770.21 2.6770.22a 1.4070.11c 1.4770.12c,e
Glucose AUCB2 (0–120 min, mM.h) 10.0970.78 5.5370.79c 4.4670.61c 3.2970.46c,d
Insulin (B1, ng/ml) 2.0170.11 1.8070.18 1.4770.17a 1.6170.22
Insulin (15 min, ng/ml) 7.1070.62 10.3770.82a 2.7770.16c 4.6170.73b,e,f
DPP-4 activity (B2) 14867874776 2970571144c 13366474592a 229297529c,e,g
GLP-1 (total) (B1, pM) 1.4570.75 0.3570.16a 13.7573.08b 13.9273.88b,e
GLP-1 (active) (5 min, pM) 2.9070.72 7.5572.02b 3.7070.52 27.0972.20c,e,g
Vehicle or drugs were administered once a day for 3 days. The oral sucrose tolerance test was performed on Day 4 following an overnight
fast. Plasma samples were taken at baseline before drug treatment (B1, 60 min), 60 min after treatment (B2, 0 min), and 5, 15, 30, 60, and
120 min following a sucrose (4 g/kg po) challenge. AUCB2 refers to the area under the curve above B2 baseline for the 0–30 min and 0–
120 min time periods. Data are shown as adjusted means (n¼9–10)7S.E.M. (Calculated from the residuals of the statistical model).
a Po0.05 versus vehicle-controls.
b Po0.01 versus vehicle-controls.
c Po0.001 versus vehicle-controls.
d Po0.05 combination versus linagliptin.
e Po0.001 combination versus linagliptin.
f Po0.01 combination versus voglibose.
g Po0.001 combination versus voglibose.
Fig. 2. Effect of linagliptin (1 mg/kg po) and voglibose (1 mg/kg po), alone and in combination, on (A) body weight, and (B) plasma glucose levels during an oral sucrose
tolerance test, in male ZDF rats. Vehicle or drugs were administered once a day for 3 days. The oral sucrose tolerance test was performed on Day 4 following an overnight fast.
Plasma samples were taken before drug treatment (B1); 60 min after treatment (B2, 0 min) and 5, 15, 30, 60, and 120 min following a sucrose (4 g/kg po) challenge. Data are
shown as adjusted means (n¼10)7S.E.M. (Calculated from the residuals of the statistical model). nPo0.05, nnPo0.01, nnnPo0.001 versus vehicle-controls, ΨΨPo0.01,
ΨΨΨPo0.001 combination versus linagliptin, δPo0.05, δδPo0.01, δδδPo0.001 combination versus voglibose. The colours of the symbols match the corresponding graph. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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None of the treatments signiﬁcantly altered plasma insulin at
B1, however, plasma insulin levels were signiﬁcantly increased by
linagliptin and signiﬁcantly reduced by voglibose (1 mg/kg po)
15 min post-sucrose, compared to the control group (Table 2).
Plasma insulin levels of animals given the combination were
similar to the vehicle-treated controls, and signiﬁcantly lower
than the linagliptin group, 15 min after the sucrose challenge
(Table 2).
Plasma DPP-4 activity at B2 was signiﬁcantly inhibited by
linagliptin, voglibose (1 mg/kg po) and the combination of drugs,
compared to the controls (Table 2). This response was signiﬁcantly
greater in rats given the combination compared to linagliptin or
voglibose (1 mg/kg po) alone (Table 2).
In this study, linagliptin did not signiﬁcantly alter plasma levels
of total GLP-1 at B1, compared to the control group (Table 2). A
signiﬁcant increase in total GLP-1 was observed in the rats given
voglibose (1 mg/kg po) but not in animals given the combination
of linagliptin with voglibose (1 mg/kg po). The effects of this
lower dose of voglibose on total GLP-1 levels were quite variable
(as shown by the magnitude of the S.E.M.), which may explain
these ﬁndings (Table 2). In comparison, plasma levels of active
GLP-1 (5 min post-sucrose) were signiﬁcantly increased by lina-
gliptin and the combination of linagliptin and voglibose (1 mg/kg
po), but not by voglibose (1 mg/kg po) alone, compared to the
control group (Table 2). The increase in active GLP-1 produced by
the combination of the two drugs was markedly (and signiﬁcantly)
greater than the increase in plasma GLP-1 (active) produced by
linagliptin alone (Table 2).
3.2. Linagliptin and exendin-4
Linagliptin (1 mg/kg po) produced a small, transient decrease
in body weight (Day 2 only) compared to the control group
(Fig. 3A). Exendin-4 (10 μg/kg sc), and the combination of lina-
gliptin and exendin-4, signiﬁcantly reduced body weight on Days
2, 3 and 4, compared to the controls (Fig. 3A). Body weights of rats
given the combination were similar to those of the exendin-4
Table 2
Effect of linagliptin (1 mg/kg po) and voglibose (1 mg/kg po), alone and in combination, on various plasma parameters during an oral sucrose
tolerance test in male ZDF rats.
Plasma parameter Vehicle po Linagliptin
1 mg/kg po
Voglibose
1 mg/kg po
Linagliptin 1 mg/kg poþ
voglibose 1 mg/kg po
Glucose AUCB2 (0–30 min, mM.h) 2.8970.29 2.1370.21a 1.5270.33c 1.6470.13c
Glucose AUCB2 (0–120 min, mM.h) 8.9870.88 3.7371.02c 4.5471.44b 4.8870.60b
Insulin (B1, ng/ml) 3.7670.18 4.3570.61 3.3470.44 3.9870.43
Insulin (15 min, ng/ml) 5.6270.68 9.0770.88a 3.6670.53a 4.6770.76f
DPP-4 activity (B2) 154,72075415 27,70271347c 133,469710005a 23,62874465c,d,g
GLP-1 (total) (B1, pM) 2.8371.87 0.7170.43 17.6779.59a 8.2972.18e
GLP-1 (active) (5 min, pM) 2.3570.77 5.7370.74c 2.8871.39 17.3773.23c,f,g
Vehicle or drugs were administered once a day for 3 days. The oral sucrose tolerance test was performed on Day 4 following an overnight
fast. Plasma samples were taken at baseline before drug treatment (B1, 60 min), 60 min after treatment (B2, 0 min), and 5, 15, 30, 60, and
120 min following a sucrose (4 g/kg po) challenge. AUCB2 refers to the area under the curve above B2 baseline for the 0–30 min and
0–120 min time periods. Data are shown as adjusted means (n¼10)7S.E.M. (Calculated from the residuals of the statistical model).
a Po0.05 versus vehicle-controls.
b Po0.01 versus vehicle-controls.
c Po0.001 versus vehicle-controls.
d Po0.05 combination versus linagliptin.
e Po0.01 combination versus linagliptin.
f Po0.001 combination versus linagliptin.
g Po0.001 combination versus voglibose.
Fig. 3. Effect of linagliptin (1 mg/kg po) and exendin-4 (10 μg/kg sc), alone and in combination, on (A) body weight, and (B) plasma glucose levels during an oral glucose
tolerance test, in male ZDF rats. Vehicle or drugs were administered once a day for 3 days. The oral glucose tolerance test was performed on Day 4 following an overnight fast.
Plasma samples were taken before drug treatment (B1); 60 min after treatment (B2, 0 min) and 5, 15, 30, 60, and 120 min following a glucose (2 g/kg po) challenge. Data are
shown as adjusted means (n¼10)7S.E.M. (Calculated from the residuals of the statistical model). nPo0.05, nnPo0.01, nnnPo0.001 versus vehicle-controls, ΨPo0.05,
ΨΨPo0.01, ΨΨΨPo0.001 combination versus linagliptin, δPo0.05, δδPo0.01 combination versus exendin-4. The colours of the symbols match the corresponding graph. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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group and signiﬁcantly lower than those of the linagliptin-treated
rats throughout treatment (Fig. 3A).
Plasma glucose levels of the linagliptin group were not signiﬁ-
cantly altered at B1, but were signiﬁcantly reduced in rats given
exendin-4 or the combination of drugs, compared to the control
group (Fig. 3B). Plasma glucose levels of rats given the combination
were signiﬁcantly lower than the linagliptin group at B1 (Fig. 3B).
Exendin-4 produced a small, signiﬁcant increase in plasma glucose
compared to the control group at B2 (Fig. 3B). This response was not
observed in rats given linagliptin and exendin-4. All drug treat-
ments signiﬁcantly reduced plasma glucose compared to the con-
trol group following the glucose challenge as shown by the time
course and AUCB2 data (Fig. 3B and Table 3).
Plasma glucose levels of animals given the combination of
drugs were signiﬁcantly lower than those of the exendin-4 group
at 5 min post-glucose and the linagliptin group at 15 min post-
glucose but were signiﬁcantly higher than those of the linagliptin
group at 60 and 120 min post-glucose (Fig. 3B). The combination
of drugs produced a signiﬁcantly greater reduction in plasma
glucose AUCB20–30 min than linagliptin alone (Table 3). These
differences were not apparent when the data were expressed as
plasma glucose AUCB20–120 min consistent with the time-course
data (Fig. 3B and Table 3).
None of the drug treatments signiﬁcantly altered plasma
insulin at B1, compared to the vehicle-treated control group
(Table 3). Linagliptin signiﬁcantly increased plasma insulin at
15 min post-glucose whereas exendin-4 and the combination of
drugs signiﬁcantly reduced this parameter, compared to the
controls (Table 3). Plasma insulin levels of the rats given linagliptin
and exendin-4 were signiﬁcantly lower than those of the linaglip-
tin group 15 min following the glucose challenge (Table 3).
Plasma DPP-4 activity was markedly inhibited by linagliptin
and the combination of linagliptin and exendin-4, at B2, compared
to the control animals whereas exendin-4 did not alter this
parameter (Table 3).
Plasma total GLP-1 levels at B1 were not signiﬁcantly altered in
the animals given linagliptin, exendin-4 or the combination of
linagliptin with exendin-4, compared to the control group
(Table 3). However, plasma levels of active GLP-1 (determined
5 min post-glucose) were signiﬁcantly increased by linagliptin,
signiﬁcantly reduced by exendin-4, but not signiﬁcantly altered in
animals given the combination of drugs, compared to the vehicle-
treated controls (Table 3). Thus, plasma levels of GLP-1 (active) of
the rats given the combination were signiﬁcantly lower than those
of the linagliptin group at 5 min post-glucose (Table 3).
4. Discussion
This study investigated whether combinations of linagliptin
with voglibose or exendin-4 improved glycaemic control, com-
pared to the drugs alone, in male ZDF rats. The animals exhibited
raised fasting plasma glucose and insulin at the start of the study
which slowly increased with time consistent with a slight pro-
gression in the severity of diabetes. These ﬁndings were as
expected in this animal model of type 2 diabetes.
Three separate experiments were performed using the same
animals. In each case, drugs were given over 4 days. Steady-state
levels of linagliptin should be achieved during this period as it
binds strongly to its target tissues, effectively saturating their
binding capacity even at low doses, and has a long terminal half-
life (Fuchs et al., 2009; Graefe-Mody et al., 2012). In comparison,
voglibose is poorly absorbed from the gastrointestinal tract (Fuder
et al., 1997; Göke et al., 1995) whereas exendin-4 has a relatively
short half-life (Gao and Jusko, 2011). It could be argued that as
animals were re-used, residual effects of linagliptin may have
occurred. However, this is unlikely as linagliptin does not accu-
mulate in tissues (Fuchs et al., 2009) and animals were given at
least 9 treatment-free days between studies. Furthermore, the
experimental design controlled for previous drug history and
while some differences in plasma parameters (notably GLP-1
active and insulin) were observed in the linagliptin groups, these
changes were not signiﬁcant.
Sucrose was used as the challenge in the studies with voglibose
due to its primary mode of action. Voglibose inhibits the break-
down of complex carbohydrates in the intestine and would be
expected to increase circulating levels of fructose. Fructose has a
low glycaemic index and when administered acutely leads to a
relatively small increase in plasma glucose and insulin since it is
primarily cleared by the liver (Bantle, 2009). In this study, sucrose
was used at a dose producing comparable excursions in plasma
glucose and insulin to the glucose load.
Linagliptin had little or no effect on body weight consistent
with previous studies in ZDF and dietary-induced obese rats
(Thomas et al., 2009; Vickers et al., 2012) and with clinical studies
with linagliptin and other DPP-4 inhibitors (Barnett, 2006;
Table 3
Effect of linagliptin (1 mg/kg po) and exendin-4 (10 μg /kg sc), alone and in combination, on various plasma parameters during an oral glucose
tolerance test in male ZDF rats.
Plasma parameter Vehicle po/sc Linagliptin
1 mg/kg po
Exendin-4
10 lg/kg sc
Linagliptin 1 mg/kg poþ
exendin-4 10 lg/kg sc
Glucose AUCB2 (0–30 min, mM.h) 4.0370.23 2.7170.17c 2.1770.13c 2.0870.20c,d
Glucose AUCB2 (0–120 min, mM.h) 12.7670.57 6.6870.62c 7.3170.52c 7.9570.65c
Insulin (B1, ng/ml) 2.7270.25 2.3670.28 2.7770.49 2.1070.25
Insulin (15 min, ng/ml) 7.3070.76 10.3971.72a 3.9770.48b 3.6070.50c,e
DPP-4 activity (B2) 135,99074139 25,45271508c 149,27072721 28,06071197c,g
GLP-1 (total) (B1, pM) 2.5570.77 2.0570.72 3.4373.02 0.6270.28f
GLP-1 (active) (5 min, pM) 3.8070.50 13.8772.45c 1.7170.84a 3.4670.55e
Vehicle or drugs were administered once a day for 3 days. The oral glucose tolerance test was performed on Day 4 following an overnight fast. Plasma
samples were taken at baseline before drug treatment (B1, 60 min), 60 min after treatment (B2, 0 min), and 5, 15, 30, 60, and 120 min following a
glucose (2 g/kg po) challenge. AUCB2 refers to the area under the curve above B2 baseline for the 0–30 min and 0–120 min time periods. Data are
shown as adjusted means (n¼8–10)7S.E.M. (Calculated from the residuals of the statistical model).
a Po0.05 versus vehicle-controls.
b Po0.01 versus vehicle-controls.
c Po0.001 versus vehicle-controls.
d Po0.05 combination versus linagliptin.
e Po0.001 combination versus linagliptin.
f Po0.05 combination versus exendin-4.
g Po0.001 combination versus exendin-4.
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Davidson, 2009; White, 2009) which indicate that treatment with
this class of compound is essentially weight-neutral.
Linagliptin markedly improved sucrose/glucose tolerance in the
ZDF rats due to the prompt increase in insulin secretion and GLP-1
(active) in response to the sucrose/glucose load shown in each
study. The ability of linagliptin to reduce plasma glucose was most
apparent during the later parts of the tolerance tests as the
improvement in glycaemic control followed the stimulation of
insulin secretion. This time and insulin dependent effect is as
expected since absorbance of glucose is required to stimulate the
release of GLP-1 from the intestinal tract and only then can
linagliptin exert its effect to enhance the duration of action of
GLP-1 by inhibition of DPP-4. Plasma glucose levels following the
overnight fast (B1) and 60 min after dosing (B2) were not
signiﬁcantly affected by linagliptin and the drug had relatively
little effect on total GLP-1 levels at B1 conﬁrming that the effects
of linagliptin are glucose-dependent. Thus, it has minimal effects
on insulin secretion when glucose levels are relatively low which,
from a treatment point of view, reduces the risk of hypoglycaemia.
These ﬁndings, and the marked inhibition in plasma DPP-4
activity at B2 produced by linagliptin, are consistent with the
known pharmacology of linagliptin to competitively inhibit the
degradation of GLP-1, leading to an increase in circulating levels of
GLP-1 (active) and an enhanced insulin response to absorbed
glucose, and therefore improved glucose control (Thomas et al.,
2008, 2009).
Voglibose reduced body weight and improved glycaemic con-
trol in the ZDF rats. Voglibose is an α-glucosidase inhibitor and
inhibits the breakdown of complex carbohydrates in the intestine
to simple sugars, leading to delayed and reduced absorption of
monosaccharides (Göke et al., 1995). Thus, voglibose inhibited the
breakdown of sucrose to glucose and fructose. Hence, the reduced
plasma glucose and insulin excursion in the voglibose-treated
animals reﬂects an indirect effect to improve sucrose/glucose
tolerance.
Interestingly, voglibose increases GLP-1 levels in normal, ob/ob
and db/db mice (Moritoh et al., 2009, 2010) and elevates plasma
GLP-1 in type 2 diabetics (Narita et al., 2012). Indeed, it has been
suggested that the weight loss produced by voglibose may be due
to increased GLP-1 (Yamazaki et al., 2007). In the current study,
voglibose signiﬁcantly increased total GLP-1 levels at B1 but had
no effect on active GLP-1 levels 5 min post-sucrose. It signiﬁcantly
inhibited DPP-4 activity at B2, however, this response was very
small compared to the profound inhibition of DPP-4 activity
produced by linagliptin. Thus, it may be speculated that any
GLP-1 produced in response to voglibose may have been rapidly
degraded by DPP-4.
Linagliptin was evaluated in combination with voglibose at
both high (10 mg/kg po) and low (1 mg/kg po) doses. Although
voglibose at the higher dose was primarily responsible for the
observed weight loss in combination with linagliptin, at the lower
dose, both compounds appeared to contribute to the initial small
degree of weight loss observed. Both doses of voglibose produced
signiﬁcant weight-loss in animals given linagliptin compared to
linagliptin alone. This would be an advantage, if maintained, as
moderate weight-loss is recommended for all overweight or obese
individuals with type 2 diabetes (American Diabetes Association,
2012).
The combination of linagliptin and voglibose (10 mg/kg po)
signiﬁcantly improved glucose control, compared to linagliptin
alone, whereas linagliptin and the lower dose of voglibose,
signiﬁcantly improved glucose control compared to both treat-
ments (at 15 min post-sucrose). In both cases, improved glucose
control was achieved by the combination of linagliptin and
voglibose, at a lower level of insulin, compared to linagliptin
alone. The results suggest that it may be possible to use low doses
of linagliptin and voglibose to produce similar or even greater
glycaemic control than the drugs individually. One of the advan-
tages of this strategy would be a possible reduction in drug-related
side-effects.
Voglibose did not alter active GLP-1 levels at 5 min post-
sucrose. However, the combination of linagliptin and voglibose
10 mg/kg po produced a marked increase in active GLP-1 that was
much higher than that produced by linagliptin alone. Similar
results were observed when linagliptin was combined with the
lower dose of voglibose. This important ﬁnding, given the beneﬁts
of raised GLP-1 in the therapy of diabetes, is consistent with
reports that combinations of DPP-4 inhibitors and α-glucosidase
inhibitors produce large increases in plasma GLP-1 in mice
(Moritoh et al., 2010; Yamazaki et al., 2007). Furthermore, coad-
ministration of vildagliptin and voglibose caused a greater
increase in active GLP-1 than either compound alone and sig-
niﬁcantly improved glycaemic control in type 2 diabetics
(Yamaguchi et al., 2013).
Plasma DPP-4 activity was inhibited to a signiﬁcantly greater
extent in animals given linagliptin and voglibose, compared to
linagliptin alone, however, this difference was relatively small and
unlikely to have accounted for the large differences in plasma GLP-
1 levels. The most likely explanation for the increase in active GLP-
1 in rats given linagliptin and voglibose, compared to linagliptin
alone, is that linagliptin prevented the degradation of GLP-1
secreted in response to voglibose.
The long-acting GLP-1 analogue, exendin-4, signiﬁcantly
reduced body weight and improved glucose tolerance but sig-
niﬁcantly reduced plasma GLP-1 (active) 5 min post-glucose.
Previous studies in animals and man have shown that exendin-4
reduces body weight as food intake is reduced due to increased
satiety associated with inhibition of gastric emptying (Cvetković
and Plosker, 2007; Mack et al., 2006; Young et al., 1999). Although
exendin-4 might be expected to stimulate insulin secretion,
particularly in combination with a glucose load, this was not
observed. This may have been because the timing of the admin-
istration of exendin-4 (60 min before glucose) or the plasma
sampling (15 min post-glucose) may not have been optimal to
detect this response. However, previous studies indicate that
maximal effects on GLP-1 and insulin would be expected at these
time-points (Thomas et al., 2009; Young et al., 1999). Alternatively,
exendin-4 has been shown to increase plasma glucose acutely in
rats by activating the sympathetic nervous system (Pérez-Tilve
et al., 2010). Such an action would oppose the expected beneﬁts of
exendin-4 possibly leading to a reduced insulin response. The
decrease in plasma GLP-1 (active) by exendin-4 may be attributed
to negative feedback.
Linagliptin and exendin-4 produced similar improvements in
glycaemic control. The combination of the two drugs signiﬁcantly
reduced body weight and produced a signiﬁcantly greater reduc-
tion in plasma glucose at the early time-points following the
glucose load, compared to linagliptin alone. Overall, however, the
combination of the two drugs did not markedly improve glucose
control compared to its individual constituents. This was perhaps
as expected as the drugs operate through a common mechanism,
thus any reduction in endogenously secreted GLP-1 by exendin-4
would theoretically reduce the potential beneﬁt of DPP-4 inhibi-
tors to enhance its effect. It cannot be ruled out that at lower
doses, additive effects of linagliptin and exendin-4 may emerge.
5. Conclusions
The improvements in glycaemic control and reductions in body
weights observed in male ZDF rats given linagliptin and voglibose
indicates that the combination of the two drugs may be a valuable
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new therapy for the treatment of diabetic patients. These effects
would appear to be due, at least in part, to the different but
complementary effects of linagliptin and voglibose on the GLP-1
system.
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